03/06/2026
“All three systematic reviews concluded that there is no significant difference between the two treatments regarding symptom severity and functional status in the short term. Only one SR reported significantly better scores for symptom severity and functional status in the mid and long term (>1 month to >6 months). Two SRs measured electrodiagnostic parameters such as DML, SNAPA, CMAPA, and CMAPL which only changed inconsistently over the two SRs [132], [133],
[136]. Three SRs conducted a subgroup analysis to compare rESWT to fESWT [132], [134], [136].
Two SRs concluded that rESWT is more effective than fESWT in improving the VAS, BCTQS, and BCTQf score in the mid to long term (> 1 month to >6 months) [134], [136]. Kim et al. reported no significant difference between rESWT and fESWT [132].“
https://pmc.ncbi.nlm.nih.gov/articles/PMC12833726/